Alpha 2.0
Login Register
» Authors » V Buckalew

V Buckalew

Explore the profile of V Buckalew including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 39
Followers 0
Related Specialties
Gynecology & Obstetrics
Cardiology & Vascular Diseases
Emergency Medicine
Top 10 Co-Authors
C D Adair
A J Worthy
R R Luther
J-C Veille
C Evans
W J Mroczek
Y Wang
D A Ruff
D McGuire
S Oparil
Published In
J Cardiovasc Pharmacol
Acad Emerg Med
Am J Nephrol
J Perinatol
Am Heart J
Affiliations
Soon will be listed here.
Recent Articles
1.
PP087. Deep trial secondary analysis: Digoxin immune fab fragment treatment has additional benefits in endogenous digitalis-like factor positive preeclamptic women
Graves S, Hopoate-Sitake M, Johnston A, Buckalew V, Lam G, Mason L, et al.
Pregnancy Hypertens . 2015 Jun; 2(3):287-8. PMID: 26105409
Introduction: A double blinded placebo controlled clinical trial of a commercial digoxin immune Fab fragment (DIF) in preeclamptic (PE) women provided some benefit to treated subjects (1). In that study...
2.
Erythrocyte sodium/potassium ATPase activity in severe preeclampsia
Adair C, Haupert Jr G, Koh H, Wang Y, Veille J, Buckalew V
J Perinatol . 2009 Jan; 29(4):280-3. PMID: 19158804
Objective: Elevated blood levels of endogenous digitalis-like factors (EDLF) may decrease erythrocyte sodium pump activity in preeclampsia. As the highest EDLF levels might be expected in severe preeclampsia, we investigated...
3.
Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group
Tumlin J, Dunbar L, Oparil S, Buckalew V, Ram C, Mathur V, et al.
Acad Emerg Med . 2000 Jul; 7(6):653-62. PMID: 10905644
Unlabelled: Despite successful therapies for chronic hypertension, hospital admissions for hypertensive emergency more than tripled between 1983 and 1992. Objective: To examine the safety and efficacy of fenoldopam, the first...
4.
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group
Neutel J, Buckalew V, Chrysant S, Mroczek W, Ruff D, Weber M
Am Heart J . 1999 Jan; 137(1):118-25. PMID: 9878944
Background: Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an alternative to angiotensin-converting enzyme inhibitors in the treatment of hypertension. Tasosartan is a newly developed...
5.
Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin
Adair C, Buckalew V, Taylor K, Ernest J, Frye A, Evans C, et al.
Am J Nephrol . 1996 Jan; 16(6):529-31. PMID: 8955766
We report a case of a second trimester multifetal pregnancy with preeclampsia associated with an elevated digoxin-like immune factor. Due to the remoteness from viability the patient was offered therapy...
6.
The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group
Borhani N, Bond M, Sowers J, Buckalew V, Gibbons M, Worthy A
J Cardiovasc Pharmacol . 1991 Jan; 18 Suppl 3:S15-9. PMID: 1720479
Hypertension is a risk factor for the development of atherosclerosis and its complications, which are among the major causes of morbidity and mortality. Although recent clinical trials indicate that antihypertensive...